177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy May 3, 2019 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Load more HOT NEWS Prize winning early detection research Happy 29th Birthday OncoLink! What to Say to Someone With Cancer: A Patient Perspective How can we improve LGBTQ+ cancer care? – That Cancer Conversation...
